{"transactions":[{"id":729513,"issuer":{"id":6537,"kind":"organization","name":"KAZIA THERAPEUTICS LTD"},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-23T22:47:31.000Z","date":"2026-06-19","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of 200,000 options over ADSs on June 19, 2026, at an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of 200,000 options over ADSs on June 19, 2026, at an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of 200,000 options over ADSs on June 19, 2026, at an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029."}],"balance_after":200000,"derivative":{"exercise_price":13.86,"underlying":"ADSs","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001213900-26-071231","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026071231/ownership.xml","form_type":"4"}},{"id":1207713,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2025-03-13T20:05:04.000Z","date":"2025-03-11","kind":"grant","planned":false,"acquired":true,"shares":332621,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person."}],"balance_after":1295117,"derivative":{"exercise_price":3.58,"expiration_date":"2035-03-11","underlying":"Common Stock","underlying_shares":332621},"source":{"system":"sec-edgar","filing":"0000950170-25-038708","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000095017025038708/ownership.xml","form_type":"4"}},{"id":1326556,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-18T21:37:28.000Z","date":"2024-12-18","kind":"purchase","planned":false,"acquired":true,"shares":2400,"price":5,"value":12000.0,"ownership":{"direct":false,"nature":"By Wife"},"balance_after":67716,"source":{"system":"sec-edgar","filing":"0000950170-24-137938","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000095017024137938/ownership.xml","form_type":"4"}},{"id":1326555,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-18T21:37:28.000Z","date":"2024-12-17","kind":"purchase","planned":false,"acquired":true,"shares":2752,"price":5.4162,"value":14905.3824,"ownership":{"direct":false,"nature":"By Wife"},"balance_after":65316,"source":{"system":"sec-edgar","filing":"0000950170-24-137938","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000095017024137938/ownership.xml","form_type":"4"}},{"id":1326554,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-18T21:37:28.000Z","date":"2024-12-16","kind":"purchase","planned":false,"acquired":true,"shares":2564,"price":3.83,"value":9820.12,"ownership":{"direct":false,"nature":"By Wife"},"balance_after":62564,"source":{"system":"sec-edgar","filing":"0000950170-24-137938","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000095017024137938/ownership.xml","form_type":"4"}},{"id":1589041,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2024-03-07T23:40:15.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":205008,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option will vest on March 7, 2025 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person."}],"balance_after":962496,"derivative":{"exercise_price":3.51,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":205008},"source":{"system":"sec-edgar","filing":"0001628280-24-009748","document":"wk-form4_1709854805.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000162828024009748/wk-form4_1709854805.xml","form_type":"4"}},{"id":1949961,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2023-03-16T21:42:11.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":197472,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option will vest on March 15, 2024 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person."}],"balance_after":757488,"derivative":{"exercise_price":1.72,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":197472},"source":{"system":"sec-edgar","filing":"0001628280-23-008356","document":"wf-form4_167900291678685.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000162828023008356/wf-form4_167900291678685.xml","form_type":"4"}},{"id":2155560,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-09-19T12:37:06.000Z","date":"2022-09-16","kind":"purchase","acquired":true,"shares":30000,"price":1.557,"value":46710.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.555 to $1.56. Full information regarding the number of shares purcahsed at each separate price can be furnished to the SEC staff upon request."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001628280-22-025099","document":"wf-form4_166359101233703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000162828022025099/wf-form4_166359101233703.xml","form_type":"4"}},{"id":2339752,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2022-03-10T23:40:57.000Z","date":"2022-03-09","kind":"grant","acquired":true,"shares":170016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"42,504 vest on 3/09/2023. 3,542 vest monthly for 36 months beginning on 4/09/2023 through 3/09/2026."}],"balance_after":560016,"derivative":{"exercise_price":2.5,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":170016},"source":{"system":"sec-edgar","filing":"0001628280-22-005792","document":"wf-form4_164695562170769.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000162828022005792/wf-form4_164695562170769.xml","form_type":"4"}},{"id":2571921,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-13T12:12:36.000Z","date":"2021-09-10","kind":"purchase","acquired":true,"shares":5000,"price":6.32,"value":31600.0,"ownership":{"direct":true},"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001628280-21-018433","document":"wf-form4_163153514276157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000162828021018433/wf-form4_163153514276157.xml","form_type":"4"}},{"id":2571920,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-13T12:12:36.000Z","date":"2021-09-10","kind":"purchase","acquired":true,"shares":5000,"price":6.35,"value":31750.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001628280-21-018433","document":"wf-form4_163153514276157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000162828021018433/wf-form4_163153514276157.xml","form_type":"4"}},{"id":2571919,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-13T12:12:36.000Z","date":"2021-09-10","kind":"purchase","acquired":true,"shares":10000,"price":6.38,"value":63800.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001628280-21-018433","document":"wf-form4_163153514276157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000162828021018433/wf-form4_163153514276157.xml","form_type":"4"}},{"id":2571918,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-13T12:12:36.000Z","date":"2021-09-10","kind":"purchase","acquired":true,"shares":5000,"price":6.75,"value":33750.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001628280-21-018433","document":"wf-form4_163153514276157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000162828021018433/wf-form4_163153514276157.xml","form_type":"4"}},{"id":2571917,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-13T12:12:36.000Z","date":"2021-09-10","kind":"purchase","acquired":true,"shares":5000,"price":6.62,"value":33100.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001628280-21-018433","document":"wf-form4_163153514276157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000162828021018433/wf-form4_163153514276157.xml","form_type":"4"}},{"id":2636102,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-07-12T20:16:15.000Z","date":"2021-07-12","kind":"grant","acquired":true,"shares":390000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"97,500 vest on 7/12/2022. 8,125 vest monthly for 36 months beginning on 8/12/2022 through 7/12/2025."}],"balance_after":390000,"derivative":{"exercise_price":6.55,"expiration_date":"2031-07-12","underlying":"Stock Options","underlying_shares":390000},"source":{"system":"sec-edgar","filing":"0001628280-21-013754","document":"wf-form4_162612095825628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000162828021013754/wf-form4_162612095825628.xml","form_type":"4"}},{"id":2777516,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-03-20T01:12:52.000Z","date":"2021-03-17","kind":"grant","acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 17, 2021."}],"balance_after":130000,"derivative":{"exercise_price":2.55,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001610618-21-000024","document":"wf-form4_161620275828794.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000161061821000024/wf-form4_161620275828794.xml","form_type":"4"}},{"id":2983424,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-11-12T11:00:42.000Z","date":"2020-11-10","kind":"purchase","acquired":true,"shares":50000,"price":2.0144,"value":100720.0,"ownership":{"direct":false,"nature":"by spouse's IRA"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.97\nto $2.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set\nforth above."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001209191-20-057806","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000120919120057806/doc4.xml","form_type":"4"}},{"id":3197873,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-03-23T23:16:02.000Z","date":"2020-03-19","kind":"exercise","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 19, 2020."}],"balance_after":110000,"derivative":{"exercise_price":1.98,"expiration_date":"2030-03-18","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-20-020747","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000120919120020747/doc4.xml","form_type":"4"}},{"id":3197872,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-03-23T23:16:02.000Z","date":"2020-03-19","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 3, 2018, the reporting person was granted a performance-based restricted stock unit (RSU) which would vest upon the achievement of various clinical and corporate milestones. On March 19, 2020 the Board accelerated the vesting of the RSU in full."},{"field":"shares","element":"transactionShares","label":"F1","text":"On December 3, 2018, the reporting person was granted a performance-based restricted stock unit (RSU) which would vest upon the achievement of various clinical and corporate milestones. On March 19, 2020 the Board accelerated the vesting of the RSU in full."}],"balance_after":61891,"source":{"system":"sec-edgar","filing":"0001209191-20-020747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000120919120020747/doc4.xml","form_type":"4"}},{"id":3197871,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-03-23T23:12:29.000Z","date":"2019-09-24","kind":"purchase","acquired":true,"shares":30000,"price":1.908,"value":57240.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90\nto $1.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set\nforth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On September 26, 2019, the reporting person filed a Form 4 which inadvertently reported that, following his open market purchase, he held 205,000 shares of the issuer's common stock.  In fact, as reported in this amendment, the reporting person directly owned 30,000 shares of common stock."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-20-020744","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000120919120020744/doc4a.xml","form_type":"4/A","original_submission_date":"2019-09-26"}},{"id":3297719,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Subscription Rights (right to buy)","published_at":"2020-01-31T01:49:44.000Z","date":"2020-01-28","kind":"other","acquired":false,"shares":6891,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of irrevocable subscription rights to acquire shares of Common Stock after the completion of the subscription period of Issuer's rights offering, which is expected to be February 10, 2020."}],"balance_after":0,"derivative":{"exercise_price":2.51,"exercise_date":"2020-01-22","expiration_date":"2020-02-10","underlying":"Common Stock","underlying_shares":6891},"source":{"system":"sec-edgar","filing":"0001209191-20-005704","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000120919120005704/doc4.xml","form_type":"4"}},{"id":3297718,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-01-31T01:49:44.000Z","date":"2020-01-28","kind":"other","acquired":true,"shares":6891,"price":2.51,"value":17296.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of irrevocable subscription rights to acquire shares of Common Stock after the completion of the subscription period of Issuer's rights offering, which is expected to be February 10, 2020."}],"balance_after":211891,"source":{"system":"sec-edgar","filing":"0001209191-20-005704","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000120919120005704/doc4.xml","form_type":"4"}},{"id":3405751,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-09-27T01:17:27.000Z","date":"2019-09-24","kind":"purchase","acquired":true,"shares":30000,"price":1.908,"value":57240.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90\nto $1.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set\nforth above."}],"balance_after":205000,"source":{"system":"sec-edgar","filing":"0001209191-19-050922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000120919119050922/doc4.xml","form_type":"4"}},{"id":3743542,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-12-04T23:57:10.000Z","date":"2018-12-03","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of December 3, 2018; 1/48th of the shares subject to the option shall vest monthly thereafter, such that all shares will be vested on December 3, 2022."}],"balance_after":175000,"derivative":{"exercise_price":3.62,"expiration_date":"2028-12-02","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-18-061051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463151/000120919118061051/doc4.xml","form_type":"4"}}]}